On March 17–18, 2018, the Personalizing Inflammatory Bowel Disease Treatment symposium was held at the Pan Pacific Hotel in Melbourne, Australia. This was the second biennial meeting for the Australian inflammatory bowel disease (IBD) community, supported by Takeda Australia. The independent steering committee of Dr. Jakob Begun (Chair), Professor Rupert Leong, Dr. Réme Mountifield, and Associate Professor Miles Sparrow developed the content of the meeting and choice of speakers. While sponsored by Takeda Australia, they were not involved in the development of the program. Two international speakers, Dr. Ashwin Ananthakrishnan, Director of the Massachusetts General Hospital Crohn's and Colitis Center, USA, and Dr. Miles Parkes, Director of Gastroenterology, Addenbrooke's Hospital, UK, joined local speakers to provide a program exploring contemporary topics related to IBD. Over five sessions, the audience were provided with an overview of current and future treatments for IBD. On the first day, session 1, Predictors in IBD—looking in to the magic ball, focused on the use of current and next-generation clinical predictors and the complexity of risk stratification in real life. Session 2, Positioning biological agents, highlighted the current criteria for prescribing biological agents in Australia and was followed by an interactive case-based panel discussion. Session 3, The epidemiology of IBD—nature versus nurture: genes versus the environment, focused on the role of the environment in IBD and concluded with a lively debate between our two international speakers on the cause, environmental or genetic, of IBD. Pre-debate and post-debate audience polling showed overwhelming support for the environmental argument (pre-poll 74% environment vs 26% genetics; post-poll 71% environment vs 29% genetics), although both debaters agreed that both genetics and the environment contribute to the development of IBD. The second day, session 4, Selectively targeting the gut in IBD, reviewed the current evidence for targeting integrins and the role of the gut microbiome in IBD. This session finished with a review of real-world evidence for vedolizumab. The symposium's final session, Preventing disasters in IBD—how we can help our patients and each other, included the presentation of cases that resulted in adverse outcomes. Other presentations during this session included a review of a new clinical management tool that will assist practitioners with daily IBD patient care, while simultaneously collecting long-term, real-world evidence and safety data. Other presentations included a discussion of the results of the Crohn's and Colitis Australia (CCA) audit and the role of professional bodies representing those with an interest in IBD. Throughout the symposium, there was lively discussion about the cause, optimal treatment regimens, and risk stratification for patients with IBD. The case-based discussions over the 2 days highlighted the importance of individualizing treatment based on the patient's presentation, stage of disease, and their personal priorities. The impact of environment on the development of IBD was also a consistent theme throughout the symposium, highlighting an area that continues to cause debate and one of continued study. Included in this Journal of Gastroenterology and Hepatology supplement is a brief overview of each symposium session and a summary of each presentation within the session. We hope that you find these summaries useful and informative. JB has received honorariums and consulting fees from Takeda and Janssen-Cilag.